Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

NCT05095636 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

102

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer
Metastasis

Interventions

DRUG: Apatinib Mesylate
DRUG: Camrelizumab

Sponsor

Fudan University